Cullinan Therapeutics, Inc. Common Stock

CGEMNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
20.54 USD
↗ 0.14 (0.69%)AT CLOSE (11:59 AM EDT)
20.53
↘ 0.01 (0.04%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
20.53
↘ 0.01 (0.04%)
🔴Market: CLOSED

Cullinan Therapeutics, Inc. Common Stock (CGEM) is currently trading at $20.55. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place CGEM at a fair price relative to peers.

Technical & fundamental data as of Sep 15, 2026.

Open?$20.38
High?$20.71
Low?$19.64
Prev. Close?$20.40
Volume?1.1M
Avg. Volume?769.2K
VWAP?$20.25
Rel. Volume?1.38x
Bid / Ask
Bid?$19.86 × 200
Ask?$21.20 × 100
Spread?$1.34
Midpoint?$20.53
Valuation & Ratios
Market Cap?1.3B
Shares Out?64.4M
Float?53.5M
Float %?83.2%
P/E Ratio?N/A
P/B Ratio?4.11
EPS?-$2.78
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
109
Market Cap
1.3B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cullinantherapeutics.com
Listed
2021-01-08
Address
ONE MAIN STREET
CAMBRIDGE, MA 02142
Phone: 617-410-4650
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?15.19Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?19.37%High
Short Interest?10.4M
Days to Cover?15.5
Free Float53.5M
Avg Daily Volume669.8K
Settlement Date2026-08-31
Financial Health
Current Ratio?8.42Strong
Quick Ratio?8.42Strong
Cash Ratio?1.94Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
43
4.11FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-55.6%WEAK▾
ROA?
S&P
3
-49.2%WEAK▾
Cash Flow & Enterprise
FCF?$-159299000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist